Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -0.6%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $2M | $1M | $2M | $6M | — | — |
| Enterprise Value | $-1644263859 | $-1644714509 | $-2392993 | $5M | — | — |
| P/E Ratio → | -0.07 | — | — | — | — | — |
| P/S Ratio | — | — | 0.21 | 9.24 | — | — |
| P/B Ratio | 0.00 | 0.00 | 0.28 | 2.18 | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | -0.32 | 7.91 | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | -146468.5% | -1086.1% | -3328.7% | -8383.1% |
| Net Profit Margin | — | — | -119.6% | -1644.9% | -3760.7% | -8127.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -0.6% | -0.6% | -208.3% | -387.3% | — | — |
| ROA | -0.4% | -0.4% | -143.8% | -183.7% | -123.0% | -87.6% |
| ROIC | -0.8% | -0.8% | -445079.8% | -279.0% | — | — |
| ROCE | -0.6% | -0.6% | -231382.1% | -176.2% | -135.7% | -102.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.10 | 0.30 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.43 | -0.70 | -0.31 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -1441.87 | -1441.87 | -735.72 | -66.17 | -41.40 | -132.49 |
Net cash position: cash ($2.1B) exceeds total debt ($422M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 2.83 | 2.83 | 3.80 | 1.58 | 1.86 | 7.02 |
| Quick Ratio | 2.83 | 2.83 | 3.80 | 1.58 | 1.86 | 7.02 |
| Cash Ratio | 1.94 | 1.94 | 3.31 | 1.12 | 1.57 | 6.65 |
| Asset Turnover | — | — | 1.02 | 0.13 | 0.04 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 4.96 | 118.90 | 342.13 | 1108.86 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $5M | $567568 | $34514 | $60493 | $60493 |
Clinical trial funding dependency
As reported in financial statements, Azitra's ROIC has remained deeply negative, bottoming out at -142.3% in 2024Q3, which underscores the company's inability to generate returns on its R&D investments while it continues to consume capital to fund its early-stage clinical development pipeline.
The consistently negative ROIC reflects a business model that is currently purely extractive of capital rather than productive. Investors should monitor whether the company can achieve any positive inflection in capital efficiency as it moves toward later-stage clinical trials, though current trends suggest significant ongoing value destruction.
Based on Azitra's reported figures, the company's DPO has exhibited extreme volatility, reaching 359,766 days in 2026Q1, which suggests either severe reporting errors or highly irregular payment cycles that make traditional efficiency metrics like the cash conversion cycle largely meaningless for this firm.
The lack of consistent operational data makes it impossible to assess the company's supplier leverage or working capital efficiency. Analysts should treat these figures with extreme caution, as they appear to reflect accounting anomalies rather than actual operational performance or management of trade payables.
According to recent SEC filings, Azitra's interest coverage ratio has been consistently negative, with a staggering -7430.53 in 2025Q3, indicating that the company lacks any operational earnings to support its debt obligations and remains entirely reliant on external financing to maintain its solvency.
While the D/E ratio appears low in some periods, this is a function of the company's limited access to debt markets rather than a sign of financial strength. The firm's reliance on equity-based funding is a structural necessity, and any attempt to leverage the balance sheet further would likely introduce significant refinancing risk.
As indicated by the provided data, the market's attempt to apply standard P/E or EV/EBITDA multiples to Azitra is fundamentally flawed, as the company lacks the revenue and positive earnings required to make these metrics meaningful indicators of intrinsic value or future growth potential.
Investors should instead focus on 'cash runway' and 'clinical milestone probability' as the primary valuation drivers. Using traditional multiples for a pre-revenue biotech firm obscures the binary nature of its clinical outcomes and the high probability of further dilutive equity raises.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AZTR stock.
Azitra, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Azitra, Inc.'s return on equity (ROE) is -0.6%. The historical average is -198.7%.
Based on historical data, Azitra, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.